drugset
drugset / Trial / NCT06260774

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

NCT06260774 ↗

Phase 1/2 Active not recruiting 16 enrolled TransCode Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors

Timeline

Start
2024-09-05
Primary completion
2025-09-30
Completion
2027-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TTX-MC138 Unknown 0.4 mg/kg Intravenous
Subject TTX-MC138 Unknown 0.8 mg/kg Intravenous
Subject TTX-MC138 Unknown 3.2 mg/kg Intravenous

Indications

No indication recorded.